The need for a safer NSAID: Can Ontario’s Antibe Therapeutics deliver one?

by • June 25, 2014 • Feature Slider, Featured-Slides-HomeComments (0)869

They represent one of the most widely used groups of medications in the world, generating billions of dollars annually for pharmaceutical companies. Chances are that if you’ve ever suffered from pain or inflammation, you’ve turned to a nonsteroidal anti-inflammatory drug (or NSAID for short) for relief.

(L-R) John Wallace, PhD, MBA, Chief Scientific Officer and Director; Michael Bumby, DVM, MBA, Chief Financial Officer; Daniel Legault, JD, Chief Executive Officer and Director; David Vaughan, PhD, Chief Development Officer

(L-R) John Wallace, PhD, MBA, Chief Scientific Officer and Director; Michael Bumby, DVM,
MBA, Chief Financial Officer; Daniel Legault, JD, Chief Executive Officer and Director;
David Knight, a Senior Partner at Norton Rose Fulbright


Please to view this Content. (Not a member? Join Today!)

Comments are closed.

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Login